✦ LIBER ✦

P.2.101 ‘Seroquel’ (quetiapine) in the treatment of schizophrenia — overview of efficacy data in 6 phase II/III clinical trials

✍ Scribed by G.A. Atkinson; J.S.E. Hellewell; J. Raniwalla

Book ID: 118600023
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 145 KB
Volume: 7
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(97)88735-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

65-92 - Efficacy of ‘seroquel’− (quetiap

65-92 - Efficacy of ‘seroquel’− (quetiapine) in the treatment of schizophrenia — A review of 5 phase II/III clinical trials

✍ L.R. Farrow; J.S.E. Hellewell; J. Ranlwalla 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 271 KB

P.2.089 An open-label, Japanese, phase I

P.2.089 An open-label, Japanese, phase II clinical trial of ziprasidone in the treatment of schizophrenia

✍ M. Murasaki 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 152 KB

P.2.c.006 Efficacy and clinical relevanc

P.2.c.006 Efficacy and clinical relevance of vilazodone in the treatment of major depressive disorder: a pooled analysis of phase III clinical trials

✍ A. Khan; W. Song; J. Edwards; A. Ruth 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 75 KB

P.2.c.020 The efficacy and safety of lev

P.2.c.020 The efficacy and safety of levomilnacipran in the treatment of major depressive disorder: results from a phase III clinical trial

✍ A. Bose; C. Chen; C. Gommoll; A. Ruth; J. Terner-Rosenthal 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Efficacy of iloperidone in the short-ter

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials

✍ Leslie Citrome; Xiangyi Meng; Marla Hochfeld; Stephen M Stahl 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 262 KB 👁 2 views

## Objectives The efficacy and tolerability characteristics of an antipsychotic are difficult to determine from a single registration study. We thus conducted an analysis that assessed key efficacy and tolerability outcomes __post hoc__ from four pooled short‐term (4–6 weeks) phase III studies that

P-4-33 NNC 01-0687, a selective dopamine

P-4-33 NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. A phase II clinical trial

✍ J. Karle; J. Gerlach; L. Clemmesen; L. Hansen; M. Andersen; J. Andersen; C. Fens 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 140 KB